Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | Optimizing gemcitabine in metastatic TNBC

Nathan M. Merrill, PhD, University of Michigan, Ann Arbor, MI, outlines the findings of a study which investigated the optimization of gemcitabine therapy in patients with metastatic triple-negative breast cancer (TNBC). The study identified a significant correlation of response to gemcitabine with the AKT substrate MERIT40. MERIT40 promotes repair of damage to DNA which is caused by chemotherapy and thus PI3K/AKT inhibition presents a rational synergistic partner for gemcitabine. Dr Merrill also outlines a study of MEK inhibition in combination with PI3K/AKT/MTOR in basal bladder cancer. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.